Westfield Capital Management Co. LP Sells 6,804 Shares of Sanofi (NASDAQ:SNY)

Key Points

• Westfield Capital Management Co. LP reduced its stake in Sanofi by 6.5%, holding 97,814 shares worth approximately $5.4 million after selling 6,804 shares in the first quarter.
• Despite the sell-off by Westfield, several institutional investors, including Mirae Asset Global Investments and Axxcess Wealth Management, increased their positions significantly during the same period.
• Sanofi's recent earnings report revealed EPS of $0.90, missing estimates by $0.06, with a quarterly revenue of $11.34 billion, up 7% year-over-year.

Westfield Capital Management Co. LP decreased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 6.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,814 shares of the company's stock after selling 6,804 shares during the period. Westfield Capital Management Co. LP's holdings in Sanofi were worth $5,425,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after purchasing an additional 1,869 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in Sanofi by 19.8% in the fourth quarter. CIBC Private Wealth Group LLC now owns 3,175 shares of the company's stock valued at $156,000 after buying an additional 525 shares during the period. Geode Capital Management LLC boosted its stake in Sanofi by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 257,655 shares of the company's stock valued at $12,427,000 after acquiring an additional 2,917 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Sanofi by 4.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 155,078 shares of the company's stock valued at $7,479,000 after acquiring an additional 7,123 shares during the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC acquired a new stake in Sanofi during the 4th quarter worth $906,000. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Down 0.6%

Shares of SNY stock traded down $0.28 on Friday, hitting $47.16. 2,968,334 shares of the stock were exchanged, compared to its average volume of 2,590,786. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $115.79 billion, a P/E ratio of 11.34, a price-to-earnings-growth ratio of 1.10 and a beta of 0.48. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12. The business has a 50-day moving average of $48.72 and a 200 day moving average of $52.00.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the previous year, the firm posted $1.73 earnings per share. The firm's quarterly revenue was down 7.0% on a year-over-year basis. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on SNY. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Sanofi in a research report on Tuesday. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday. Two research analysts have rated the stock with a hold rating, five have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Sanofi has an average rating of "Buy" and an average target price of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.